google-site-verification: googlec7193c3de77668c9.html

GLP-1RAs shown to reduce risk of cardiovascular death

[
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed both for Type 2 diabetes and weight loss. These drugs also have shown promise in clinical trials for patients with chronic cardiovascular, kidney, and metabolic diseases. Those studies focused mainly on patients with singular diagnoses, but these conditions often overlap.


Source link

Advertisements
Views: 4

See also  Insurance coverage and type of employment shape inequities in access to semaglutide

Check Also

Bacterial STIs reach record highs in Europe, and congenital syphilis cases nearly double

[ The latest Annual Epidemiological Reports from ECDC indicate a surge in bacterial sexually transmitted …

Can AI help predict how you might be feeling in the future?

[ Can emotions be forecasted? The question is being asked by Northeastern assistant professor and …

Researcher develops ‘smart, tiny bubbles’ to treat cancer and heart disease

[ To help accelerate the path to manufacturing the therapy for clinical use and advancing …

Leave a Reply

Available for Amazon Prime